RARRES2 and hepatocellular carcinoma: An impairment but not a complete abolition of the hepatocellular carcinoma-inhibiting effect of chemerin was observed in T-cell and B-cell deficient Rag1-/- mice and CD8+ T cell-depleted mice confirming a partial role of CD8+ T cells in the antitumoral effects of chemerin [92].